SEC	Form	4

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

	Check this box if no longer subject to
11	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)
Ц	may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule

Check this box to indicate that a

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

10b5-1(c). See I	nstruction 10.			
	ess of Reporting Pe ific Founders	rson <sup>*</sup> <u>UGP III, LLC</u>	2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>P3 Health Partners Inc.</u> [ PIII ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 06/04/2025	Officer (give title Other (specify below) below)
980 NORTH MICHIGAN AVENUE, SUITE 1900		ENUE,	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person
(Street)				X Form filed by More than One Reporting Person
CHICAGO	IL	60611		
(City)	(State)	(Zip)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

 Date (Month/Day/Year)	 Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			Securities Beneficially Owned Following Reported	Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership
	Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (Ir 8)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Reported Transaction(s (Instr. 4)			
Warrants to Purchase Class A Common Stock	\$10.34	06/04/2025 <sup>(1)</sup>		P <sup>(1)</sup>		1,428,129 <sup>(2)</sup>		(3)	(4)	Class A Common Stock	1,428,129	\$0 <sup>(5)</sup>	1,428,129	I	See Footnote <sup>(6)</sup>

1. Name and Address of Reporting  $\operatorname{Person}^{\star}$ 

Chicago Pacific Founders UGP III, LLC

(Last)	(First)	(Middle)
980 NORTH MI	CHIGAN AVENUE	l,
SUITE 1900		
(Street)		
CHICAGO	IL	60611
(City)	(State)	(Zip)
1. Name and Addres	s of Reporting Person *	
Chicago Pacit	fic Founders GP	<u>III, L.P.</u>
(Last)	(First)	(Middle)
980 NORTH MI	CHIGAN AVENUE	2,
SUITE 1900		
(Street)		
CHICAGO	IL	60611
(City)	(State)	(Zip)

Explanation of Responses:

1. On February 13, 2025, P3 Health Group, LLC ("P3 LLC"), a subsidiary of P3 Health Partners Inc. (the "Issuer"), entered into a financing transaction with VBC Growth SPV 4, LLC, a Delaware limited liability company ("VBC 4"), consisting of an unsecured promissory note and warrants to purchase 1,428,129 shares of Class A Common Stock ("Common Stock") of the Issuer. The Issuer's shareholders approved the issuance of the Common Stock underlying such warrants on June 4, 2025.

2. On April 11, 2025, the Issuer effected a 1-for-50 reverse stock split of the Issuer's issued and outstanding Common Stock. All amounts reported in this Form 4 have been adjusted to reflect the number of securities issued on an as-adjusted basis.

The warrants to purchase Common Stock are exercisable for a whole number of shares of Common Stock at any time (as described in the warrant agreement previously filed by the Issuer with the SEC).
 The warrants and the right to purchase shares of Common Stock upon the exercise of the warrants will terminate on February 13, 2032.

The warrants and the right to putchase shares of common stock upon the exclusion of the warrants with eliminate on recently 19, 2002

5. The warrants were issued in connection with a \$30 million promissory note issued on February 13, 2025 by P3 LLC to VBC 4, all of which was previously disclosed by the Issuer upon issuance of the warrants and note.

6. Chicago Pacific Founders UGP III, LLC is the general partner of Chicago Pacific Founders GP III, LP ("CPF GP"). CPF GP is the Manager of VBC 4 and has the power to vote and dispose of the Issuer's securities held by VBC 4.

 Chicago Pacific Founders UGP III.

 LLC, /s/ Michael Wilson,
 06/06/2025

 authorized signatory

 Chicago Pacific Founders GP III.

 L.P., /s/ Michael Wilson,
 06/06/2025

 authorized signatory

 \*\* Signature of Reporting Person
 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.